Causes of death in patients with epilepsy were assessed to determine the presence of cardiac pathology.
The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.
Investigators sought to examine whether seizures are capable of causing changes in serotonin levels in the peripheral circulation.
Next-generation sequencing can improve treatment efficacy and reduce hospitalization in children with drug-resistant epilepsy.
In individuals who can adequately access healthcare appointments, medications, and other treatments, the combination of driving restrictions and sparse or nonexistent public transportation options interferes with daily living and their overall quality of life.
Since MRI and EEG risk factors were retrospectively reviewed, the study was unable to analyze the temporal seizure burden or the volume of MRI injury, both of which may have provided greater insights into outcomes.
The primary efficacy outcome was achieved in a higher percentage of patients in the exposure range of 9 to 15 ng/mL compared with patients in the 3 to 7 ng/mL and >7 to 9 ng/mL ranges.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The sNDA included data from Study 311 (N=180), an ongoing, open-label, multicenter trial with an extension phase that evaluated the safety, tolerability, and exposure-efficacy relationship of Fycompa oral suspension as adjunctive therapy in children (4 to 11 years) with inadequately controlled POS or PGTC seizures.
At 8 years, the cumulative rate of any hospitalization or emergency department visit for seizure was higher among patients with stroke vs the general population.
The results of this study should help reassure and encourage women with epilepsy without a prior diagnosis of infertility or an associated disorder who are seeking pregnancy.
The effects of short-term VPA exposure on placental compound carrier expression were examined in this study.
Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndromeMay 24, 2018
Amongst adults and children with the Lennox-Gastaut syndrome, addition of cannabidiol to a conventional antiepileptic regimen reduced drop seizure frequency compared to placebo treated patients.
A majority of participants (67%) had reported seeing a neurologist or epilepsy specialist in the past year, with younger adults comprising a higher percentage of these participants.
The expanded approval was supported by extrapolated efficacy data from placebo-controlled studies in adults with partial-onset seizures.
The investigators concluded that these findings should help to identify targets for intervention to reduce the overall time to treatment in this population.
The approval was based on a 12-week, double-blind, placebo-controlled study (N=295) in pediatric patients 4-17 years of age.
The approval is specifically for bilateral anterior thalamic nucleus stimulation and is based on results from the SANTE study (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy).
Although most adults with epilepsy report taking epilepsy medication, less than half of those report having their seizures controlled.
Researchers evaluated the use of genetic screening to identify individuals who are at risk for carbamazepine-induced cutaneous adverse drug reactions.
Investigators conducted a population-based study to assess risk and cause of unnatural mortality in individuals with epilepsy.
Clinicians should conduct a medical evaluation as soon as suspicious symptoms are reported and discontinue lamotrigine if HLH is suspected.
Researchers evaluated the incidence of treatment-emergent adverse events in pediatric patients taking eslicarbazepine acetate with other antiepileptic drugs to better understand tolerability profiles.
Researchers conducted post-hoc analysis of data derived from 2 randomized, placebo-controlled trials to determine the safety and tolerability of eslicarbazepine in pediatric patients with partial-onset seizures not responsive to treatment with ≤2 antiepileptic drugs.
Prior studies have suggested that women with epilepsy who are seizure free ≥9 months prior to pregnancy have a high likelihood of remaining seizure free during pregnancy.
In the event where electroencephalograms featured either seizures or seizure-like patterns, nonexpert medical students who auditorily reviewed the electroencephalograms rated samples as seizures with a higher degree of specificity vs experts or nonexpert medical students.
Cannabidiol may be effective as add-on treatment for drop seizures associated with Lennox-Gastaut syndrome.
The risk of unnatural death is increased among people with epilepsy.
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
Because of the small size of the study sample, the findings may be limited to this patient population and may be hard to generalize across all pediatric patients with Dravet syndrome.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans